Aster Capital Management (Difc) LTD Supernus Pharmaceuticals, Inc. Call Options Transaction History
Aster Capital Management (Difc) LTD
- $262 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SUPN
# of Institutions
302Shares Held
60.6MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$413 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$244 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$192 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$114 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$104 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.13B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...